Jun. 23 at 8:23 PM
$ONCY Pfizer's CFO Dave Denton leaves Pfizer and has accepted a position with NIKE, which demonstrates that Denton's involvement in Prizer's
$43 Billion acquisition of ADC company Seagen has not gone well and will impact Pfizer's forward performance unless the company undertakes further M&A deals with biotech companies that align in combination with Pfizer's ADC portfolio, like ONCY's pelareorep.
